Skip to content
Open access

Diagnostic challenge in seronegative paranodopathies: case report of a severe phenotype

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Case Presentation: A 29-year-old male, previously healthy, developed in January 2024 progressive paresthesias associated with proximal and distal weakness in all four limbs, ultimately leading to inability to ambulate. Electroneuromyography revealed a symmetric demyelinating sensorimotor polyneuropathy with both proximal and distal involvement. Magnetic resonance imaging of the neuraxis demonstrated thickening and enhancement of cauda equina roots, while cerebrospinal fluid (CSF) analysis showed albuminocytologic dissociation (protein: 97 mg/dL). After exclusion of infectious, neoplastic, and rheumatologic etiologies, the diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) was established according to EAN/PNS 2021 criteria. Initial treatment with intravenous methylprednisolone followed by oral prednisone resulted in partial improvement. In March 2024, the patient experienced severe relapse under corticosteroid therapy, treated with intravenous immunoglobulin (IVIg), with only transient benefit. In April 2024, he rapidly deteriorated, progressing to tetraplegia, bulbar symptoms, and respiratory failure requiring mechanical ventilation. The course was further complicated by severe dysautonomia with episodes of bradycardia and asystole, necessitating permanent pacemaker implantation. Repeat CSF analysis revealed marked protein elevation (460 mg/dL). Testing for anti-neurofascin-155 and anti-contactin-1 antibodies was negative by immunocytochemistry; however, the clinical phenotype remained suggestive of paranodopathy. Given refractoriness to conventional therapy, rituximab was initiated, resulting in significant and sustained clinical improvement, including ventilator weaning, decannulation, and progressive functional recovery. Discussion: Paranodopathies represent a subgroup of demyelinating neuropathies mediated by autoantibodies against nodal and paranodal proteins such as neurofascin and contactin, frequently associated with IgG4. They are typically characterized by poor response to standard CIDP therapies, including IVIg and corticosteroids, with rituximab emerging as an effective alternative. The absence of detectable autoantibodies in this case may reflect methodological limitations, as immunocytochemistry is not recommended for screening. Cell-based assays (CBA), considered the gold standard, offer high sensitivity and specificity but remain limited in availability, representing a major diagnostic challenge. Final Comments: In severe demyelinating neuropathies, particularly when accompanied by dysautonomia and refractoriness to first-line therapies, paranodopathy should be considered even in the absence of serological confirmation. Restricted access to more sensitive diagnostic methods may contribute to underdiagnosis. Early recognition of this phenotype enables timely initiation of targeted therapies such as rituximab, with potential for significant impact on prognosis.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.